EICHORPublic-registry trials using IVA337 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
IVA337 appears in 1 registered trial Eichor's radar has found, sponsored by Inventiva Pharma, the most recent registered as Phase 2, with a planned enrollment of 42. Registered timeline: 2022–2024. The registry holds 11,826 registered studies for Diabetes Mellitus, Type 2.
| Trial | Sponsor | Condition | Phase | Sites |
| Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | PHASE2 | 42 |
| Status | Completed · planned start 2022-06 |
| Primary completion | 2024-03 |
| Enrollment target | 42 participants |
| Design | Randomized · Parallel · Phase 2 · 3 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 42 listed in Belgium, France, Netherlands, United Kingdom |
All fields verbatim from the ClinicalTrials.gov record for NCT05232071.
| First registered study | July 2015 — NCT02503644 (Inventiva Pharma) |
| Registered studies matching this name | 6 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 11,826 registered studies for Diabetes Mellitus, Type 2. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other NASH - Nonalcoholic Steatohepatitis drugs
← Eichor home · All tracked trials · NASH - Nonalcoholic Steatohepatitis studies · Weekly briefs
